GlassScriptPhysician profile
Thomas L Briscoe
NPI 1992796189
$12,944.33
in general payments reported to CMS, 2019-2025
26 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,306 · 2022: $2,313 · 2023: $3,295 · 2024: $3,593 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,050 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,050.31 |
| Education | $274.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,983.55 | 2021-2025 | |
| Janssen Biotech, INC. | $1,590.40 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $1,361.04 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $973.00 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $778.21 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $583.05 | 2022-2025 | Sotyktu, Sprycel |
| Sun Pharmaceutical Industries INC. | $547.07 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $511.96 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $459.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $445.61 | 2021-2025 | |
| Incyte Corporation | $418.98 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $392.82 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $333.18 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $328.29 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $299.24 | 2021-2025 | Nemluvio, Aklief, Epsolay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $221.26 | 2022-2023 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.30 | 2023-2025 | Spevigo |
| Almirall LLC | $156.40 | 2021-2025 | Seysara, Klisyri |
| Janssen Scientific Affairs, LLC | $154.68 | 2021-2022 | |
| Revance Therapeutics, INC. | $74.92 | 2025 | Daxxify |
| Journey Medical Corporation | $46.91 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.41 | 2022-2023 | Duobrii, Arazlo, Jublia |
| Allergan, INC. | $29.76 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.24 | 2025 | Acthar |
| Botanix Sb INC | $19.03 | 2025 | Sofdra |
| Organon LLC | $18.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Briscoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.